Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

SALVOVAR A European Multi-disciplinary Clinical Project Meant to Improve the Management of Patients with Poor Prognostic Ovarian Cancer After Neoadjuvant Chemotherapy: Restoring Hope, Salvaging Lives

Coordinator
Hospices Civils De Lyon, France
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€6.8m
Total cost
€6.8m
Partners
12 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101104469

What the project is doing

In the project's own words, from its summary on CORDIS.

The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumor debulking surgery meant to be complete (no post-operative residual lesion), and a subsequent maintenance treatment with modern targeted agents. Recent studies identified a patient population (~14,000 patients / year in Europe), whose prognostic is poor (5 year-overall survival (OS) <20%) due to a refractory cancer, characterized by a poor chemosensitivity (assessable online with the numeric CA-125 KELIMTM score <1.0), and by a disease found non-resectable disease after 3-4 cycles of chemotherapy.

In these patients, there is a high uncertainty about the best treatment adjustments to apply. SALVOVAR is a European project led by HCL, meant 1) to raise the physician awareness, and propose practical and affordable diagnostic tools for identifying these patients, and 2) to assess the utility (OS benefit), acceptability (quality-of-life; patient perception) and affordability (cost-effectiveness, including country coverage policies) of solutions based on adjustments of their medical-and-surgical treatment.

These solutions implementable in routine may improve their prognosis, according to recent literature data. The project will be based on a large pragmatic randomized phase III trial, sponsored by ARCAGY-GINECO group, and activated in 6 countries (ENGOT network; ~100 recruiting centers), with the objective of demonstrating an OS benefit with the chemotherapy densification (weekly carboplatine-paclitaxel dose-dense regimen) compared to the continuation of the standard 3-weekly regimen.

Total 685 patients treated with the standard neo-adjuvant chemotherapy will be pre-screened to randomize 240 patients. Dissemination, and communication will be carried-on to ensure the quality of the project, and inform the stakeholders, patients, public, health authorities/ payers of the project outcomes, mean to change the practices. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Topics

Who is involved

OrganisationCityCountryRole
Hospices Civils De LyonLyonFranceCoordinator
Cancer Patients EuropeBruxelles / BrusselBelgiumParticipant
European Cancer Patient CoalitionBruxelles / BrusselBelgiumParticipant
Fundacio Privada per a La Recerca I La Docencia Sant Joan De DeuEsplugues De LlobregatSpainParticipant
Parc Sanitari Sant Joan De DeuSant Boi De LlobregatSpainThird party
Arcagy AssociationParisFranceParticipant
Centre De Lutte Contre Le Cancer Leon BerardLyonFranceParticipant
Centre Hospitalier UniversitaireNimesFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Lyon Ingenierie ProjetsVilleurbanneFranceParticipant
Oncopole Claudius RegaudToulouseFranceParticipant
Susannah CarrollFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI